Trials / Completed
CompletedNCT00563771
Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome
Phase IV, Compassionate Use Program of Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To provide treatment opportunity to children and adolescent patients with hematologic malignancies by supplying the delayed marketed product and also to observe the efficacy and safety of rasburicase used in the treatment of hyperuricemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rasburicase |
Timeline
- Start date
- 2003-03-01
- Completion
- 2004-01-01
- First posted
- 2007-11-26
- Last updated
- 2008-01-28
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00563771. Inclusion in this directory is not an endorsement.